Royalty Pharma plc (NASDAQ:RPRX - Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 2,826,189 shares changed hands during mid-day trading, an increase of 8% from the previous session's volume of 2,609,791 shares.The stock last traded at $25.54 and had previously closed at $25.80.
Analysts Set New Price Targets
RPRX has been the subject of several recent research reports. The Goldman Sachs Group lifted their price target on Royalty Pharma from $50.00 to $51.00 and gave the company a "buy" rating in a research report on Wednesday, August 14th. StockNews.com raised shares of Royalty Pharma from a "hold" rating to a "buy" rating in a report on Tuesday, November 5th. Finally, Citigroup cut their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a "buy" rating for the company in a report on Friday, October 25th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $41.67.
Get Our Latest Stock Report on Royalty Pharma
Royalty Pharma Price Performance
The firm has a market capitalization of $15.27 billion, a PE ratio of 13.37, a price-to-earnings-growth ratio of 3.76 and a beta of 0.47. The stock's 50 day simple moving average is $27.42 and its two-hundred day simple moving average is $27.43. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54.
Royalty Pharma Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 3.24%. The ex-dividend date of this dividend is Friday, November 15th. Royalty Pharma's dividend payout ratio (DPR) is currently 43.52%.
Hedge Funds Weigh In On Royalty Pharma
A number of institutional investors have recently bought and sold shares of the company. Hohimer Wealth Management LLC increased its holdings in shares of Royalty Pharma by 1.0% during the 3rd quarter. Hohimer Wealth Management LLC now owns 145,357 shares of the biopharmaceutical company's stock worth $4,112,000 after buying an additional 1,445 shares during the last quarter. Geode Capital Management LLC increased its stake in Royalty Pharma by 6.1% during the third quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company's stock worth $205,562,000 after acquiring an additional 417,490 shares during the last quarter. M&T Bank Corp raised its position in Royalty Pharma by 4.3% in the third quarter. M&T Bank Corp now owns 18,749 shares of the biopharmaceutical company's stock valued at $531,000 after purchasing an additional 779 shares during the period. Barclays PLC grew its holdings in shares of Royalty Pharma by 16.3% during the 3rd quarter. Barclays PLC now owns 308,887 shares of the biopharmaceutical company's stock worth $8,737,000 after purchasing an additional 43,339 shares during the period. Finally, CTC Alternative Strategies Ltd. acquired a new stake in shares of Royalty Pharma during the 3rd quarter worth about $260,000. 54.35% of the stock is owned by hedge funds and other institutional investors.
About Royalty Pharma
(
Get Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
